|Create a new account||I have forgotten my password||Security FAQ|
Significance Statements coming to ASPET - 4/1/19.
To enhance usage and improve communication with larger and more diverse audiences, articles appearing in MOLPHARM will require a significance statement for all new submissions with an abstract starting April 1, 2019. The significance statement should succinctly explain in 1-2 sentences (120-word maximum) the relevance of the work in a broad context to a broad readership. It should identify the 2-3 most important points of the paper. A significance statement will be required for all manuscripts that contain an abstract such as articles, reviews, short communications, accelerated communications, etc., and will appear immediately after the abstract.
|MolPharm journal home||Instructions for Authors||Editorial Board||Help||Feedback|
ASPET, 1801 Rockville Pike, Suite 210, Rockville, MD, 20852-1633
Tel: 301-634-7201; Fax: 301-634-7158; Email: firstname.lastname@example.org
|© 2019 American Society for Pharmacology and Experimental Therapeutics (ASPET)|